Results 101 to 110 of about 172,128 (262)

Multi‐Targeting Carnosic Acid Kills Drug‐Resistant Helicobacter pylori With Narrow‐Spectrum Activity

open access: yesAdvanced Science, EarlyView.
Carnosic acid selectively eradicates drug‐resistant Helicobacter pylori through a multi‐targeted mechanism involving urease inhibition, membrane disruption, and biofilm eradication. It exhibits no detectable resistance, potent in vivo efficacy, and minimal impact on gut microbiota, positioning it as a promising narrow‐spectrum lead compound against ...
Yuefan Bai   +7 more
wiley   +1 more source

Ghrelin Levels in Gastric Mucosa before and after Eradication of Helicobacter pylori

open access: yesGut and Liver, 2007
Background/Aims: The relationship between Helicobacter pylori infection and ghrelin is controversial. We compared ghrelin levels in gastric mucosa and plasma between H. pylori-positive and -negative subjects, and between before and after H.
doaj   +1 more source

Inside‐Outside ROS Therapeutic Strategy Based on Piezoelectric Nano‐Urchin for Drug‐Resistant Bacteria Biofilm Infections

open access: yesAdvanced Science, EarlyView.
The contribution of this study lies not only in enabling effective treatment of drug‐resistant biofilm infections, but also in establishing a transferable therapeutic paradigm: Ultrasound‐triggered mechanical forces synergistically enhance piezoelectric polarization and nanozyme activity, driving functional ROS generation inside and outside biofilms ...
Xinjian Guo   +5 more
wiley   +1 more source

Treatment Outcome for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma according to Helicobacter pylori Infection Status: A Single-Center Experience

open access: yesGut and Liver, 2014
Background/AimsHelicobacter pylori eradication therapy has been used as a first-line treatment for H. pylori-positive gastric mucosa-associated lymphoid tissue (MALT) lymphoma. However, the management strategy for H. pylori-negative MALT lymphoma remains
doaj   +1 more source

A Biomimetic Dual‐Targeting Nano‐APA‐Editor Reprograms the 3'UTR Landscape for Tongue Squamous Cell Carcinoma Therapy

open access: yesAdvanced Science, EarlyView.
This study unveils a pathogenic axis in oral cancer where NUDT21 suppresses a tumor suppressor network, prominently PTEN, via 3'UTR lengthening. To exploit this transcriptomic vulnerability, we developed a biomimetic Nano‐APA‐editor. By delivering CRISPR/Cas9, we reprogrammed the global 3'UTR landscape, restoring multi‐target tumor suppression and ...
Yiran Ao   +5 more
wiley   +1 more source

Antigen Spreading via Localized Administration Enhances Adoptive TCR‐T Cell Therapy in Pancreatic Cancer

open access: yesAdvanced Science, EarlyView.
Cancer vaccines face limitations in pancreatic cancer due to insufficient tumor antigens. This ionic liquid ILvax via local tumor delivery triggers robust cDC1‐dependent systemic anti‐tumor immunity. It boosts endogenous CD8+ T cells and optimizes adoptive TCR‐T function, providing a promising synergistic therapeutic strategy.
Junming Huang   +11 more
wiley   +1 more source

Targeting a Myeloid–Regulatory B Cell Network Reverses Immune Paralysis in Periprosthetic Joint Infections

open access: yesAdvanced Science, EarlyView.
Periprosthetic joint infection establishes a sophisticated immunosuppressive network between CXCR4+ PMN‐MDSCs and Bregs, inducing profound CD8+ T cell paralysis. Alendronate effectively disrupts this CXCR4+ PMN‐MDSC–Breg axis by targeting STAT3, thereby restoring local immune surveillance.
Jintao Wu   +9 more
wiley   +1 more source

Polio: abandoning eradication would result in rapid resurgence of an ancient scourge

open access: yesBMJ Global Health, 2019
Roland Walter Sutter   +1 more
doaj   +1 more source

Modeling resource allocation strategies for insecticide-treated bed nets to achieve malaria eradication

open access: yeseLife
Large reductions in the global malaria burden have been achieved, but plateauing funding poses a challenge for progressing towards the ultimate goal of malaria eradication.
Nora Schmit   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy